eFFECTOR Therapeutics Inc
NASDAQ:EFTR
Intrinsic Value
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). [ Read More ]
The intrinsic value of one EFTR stock under the Base Case scenario is 4.98 USD. Compared to the current market price of 1.78 USD, eFFECTOR Therapeutics Inc is Undervalued by 64%.
Valuation Backtest
eFFECTOR Therapeutics Inc
Run backtest to discover the historical profit from buying and selling EFTR stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
eFFECTOR Therapeutics Inc
Current Assets | 19.8m |
Cash & Short-Term Investments | 18.4m |
Other Current Assets | 1.5m |
Non-Current Assets | 706k |
PP&E | 193k |
Other Non-Current Assets | 513k |
Current Liabilities | 25.8m |
Accounts Payable | 2.3m |
Accrued Liabilities | 4.1m |
Other Current Liabilities | 19.4m |
Non-Current Liabilities | 543k |
Other Non-Current Liabilities | 543k |
Earnings Waterfall
eFFECTOR Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-33.8m
USD
|
Operating Income
|
-33.8m
USD
|
Other Expenses
|
-2m
USD
|
Net Income
|
-35.8m
USD
|
Free Cash Flow Analysis
eFFECTOR Therapeutics Inc
What is Free Cash Flow?
EFTR Profitability Score
Profitability Due Diligence
eFFECTOR Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
Score
eFFECTOR Therapeutics Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
EFTR Solvency Score
Solvency Due Diligence
eFFECTOR Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Score
eFFECTOR Therapeutics Inc's solvency score is 32/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EFTR Price Targets Summary
eFFECTOR Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for EFTR is 11.22 USD with a low forecast of 10.1 USD and a high forecast of 12.6 USD.
Ownership
EFTR Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EFTR Price
eFFECTOR Therapeutics Inc
Average Annual Return | -56.08% |
Standard Deviation of Annual Returns | 54.43% |
Max Drawdown | -100% |
Market Capitalization | 6.6m USD |
Shares Outstanding | 3 687 310 |
Percentage of Shares Shorted | 9.44% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of a new class oncology drugs known as selective translation regulator inhibitors (STRIs). The company is headquartered in Solana Beach, California and currently employs 13 full-time employees. The company went IPO on 2021-01-08. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The company uses selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The firm's lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an inhibitor of programed cell death protein 1 (PD-1) in a randomized Phase IIb clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase I/II clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.
Contact
IPO
Employees
Officers
The intrinsic value of one EFTR stock under the Base Case scenario is 4.98 USD.
Compared to the current market price of 1.78 USD, eFFECTOR Therapeutics Inc is Undervalued by 64%.